Merriman Curhan Ford Said DepoMed's (DEPO) Lack of Wall Street Attention Is About to Change
Tweet Send to a Friend
Analysts at Merriman Curhan Ford reiterated their Buy rating and $10-$13 price target range on DepoMed Inc. (Nasdaq: DEPO) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
